NBNatalia V. Balashova

Natalia V. Balashova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia V. Balashova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Omega-3 fatty acids: bioavailability characteristics

    by E. V. Prokopenko, S. V. Orlova, E. A. Nikitina, N. V. Balashova, Yu. A. Pigareva

    Long-chain polyunsaturated fatty acids (PUFAs) of the omega-3 class, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have remained at the forefront of basic medicine, nutritional science, and clinical pharmacology for many decades. Large-scale epidemiological data consistently demonstrate that high consumption of marine lipids is associated with a reduced risk of cardiovascular, neurodegenerative, and systemic metabolic diseases. However, when these epidemiological observations are translated into the setting of randomized clinical trials investigating standardized omega-3 supplements and prescription formulations, the scientific community is regularly confronted with heterogeneous and, at times, directly contradictory results. Such inconsistency in clinical outcomes is driven not only by differences in study design, dosage regimens, or the severity of patients’ underlying pathology, but also by fundamental biochemical factors that are often underestimated in routine clinical practice. Of key importance are the source of the raw material, the chemical and stereochemical forms of lipid molecules, and the presence of accompanying active compounds (antioxidants and structural lipids), which together determine molecular stability, digestion kinetics, bioavailability, and the ability of active metabolites to reach target cells.

  • Open Access

    Improving the effectiveness of medical rehabilitation of patients with ischemic heart disease using dihydroquercetin

    by S. V. Orlova, E. A. Nikitina, N. V. Balashova, S. F. Ivanov, С. Л. Вольпе, V. V. Tatarinov, Yu. A. Pigareva, I. Yu. Drachev

    Cardiovascular diseases (CVD) are a leading cause of death in all industrialized countries. Coronary heart disease (CHD) occupies a leading position among CVDs. The relevance of CHD is determined by its role in disability and mortality in the population, as well as the financial costs associated with the treatment and rehabilitation of patients. The goals of treating patients with CHD are to improve quality of life by reducing the frequency of angina attacks and preventing acute myocardial infarction. In addition to lipid metabolism disorders, hemostatic disorders play a significant role in the development and progression of CHD. In particular, increased platelet activity leads to changes in blood rheology and an increased tendency to thrombosis, which leads to impaired microcirculation. Therefore, the inclusion of agents that target pathogenic mechanisms in rehabilitation programs for such patients appears promising. One such agent is the bioflavonoid dihydroquercetin (DHA), obtained from Siberian larch wood. It stimulates tissue blood flow, stabilizes microvascular barrier function, reduces capillary wall permeability, improves blood rheology, and thereby helps reduce microvascular congestion. The aim of this study was to evaluate the effectiveness of the dietary supplement «Dihydroquercetin» (Evalar, JSC) in the comprehensive treatment of patients with coronary heart disease. The study demonstrated the positive effects of dihydroquercetin on cardiovascular disease (CVD): significant improvement in peripheral microcirculation hemodynamic parameters, a tendency toward normalization of cerebral hemodynamics, and a positive effect on lipid metabolism. This opens up new possibilities for the use of plant-based antioxidants in practical medicine.

  • Open Access

    Nutritional correction of non-alcoholic fatty liver disease with the inclusion of a dietary supplement containing omega-3 PUFAs

    by S. V. Orlova, E. V. Prokopenko, E. A. Nikitina, N. V. Balashova, Yu. A. Pigareva, O. I. Tarasova, I. S. Minosyan, I. Yu. Drachev

    Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver pathologies worldwide, affecting more than a quarter of the global population. The disease is closely associated with obesity, insulin resistance, and metabolic syndrome. Although the Mediterranean diet has proven effective, adherence to it remains challenging, driving interest in combination therapy that includes dietary supplements. Omega-3 polyunsaturated fatty acids (EPA and DHA) are of particular importance, with a deficiency rate of 68.5 % in the Russian Federation and even lower levels observed in NAFLD patients. Objective. To evaluate the efficacy of the dietary supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) as part of nutritional correction in patients with NAFLD at the steatosis stage. Materials and methods. An open-label comparative 6-month study enrolled 74 patients with NAFLD. The main group (n=50) received dietary therapy plus the supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) (1 capsule/day: 950 mg omega-3 PUFAs, including not less than 550 mg EPA and not less than 230 mg DHA). The comparison group (n=24) received dietary therapy alone. Biochemical blood parameters, lipid profile, HOMA-IR index, liver enzymes, and abdominal ultrasound were assessed. Results. The main group demonstrated a significant reduction in triglycerides (from 1.29±0.06 to 1.08±0.08 mmol/L) and LDL cholesterol (from 116.3±5.04 to 103.96±3.3 mg/mL) compared to the comparison group (pConclusion. The inclusion of the dietary supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) in comprehensive dietary therapy for patients with NAFLD at the steatosis stage significantly improves lipid profile, reduces insulin resistance, alleviates cytolysis and cholestasis, and enhances patients’ quality of life. This product can be recommended as adjunctive therapy for NAFLD in combination with diet and physical activity.

  • Glycemia under control: the role of micro- and phytonutrients

    by E. A. Nikitina, S. V. Orlova, T. T. Batysheva, N. V. Balashova, M. V. Alekseeva, Yu. A. Pigareva

    Type 2 diabetes mellitus (T2DM) is a global epidemic driven by unbalanced nutrition and physical inactivity. Body weight reduction by 5% and more improves insulin sensitivity, normalizes glycemia and reduces complication risks. However, patients with T2DM frequently demonstrate deficiencies in key vitamins (C, B-complex) and minerals (magnesium, zinc, chromium), which may exacerbate metabolic disorders and increase risk of complications. Addressing these micronutrient deficiencies through dietary fiber (inulin) and phytochemicals (Gymnema sylvestre) supplementation helps improve carbohydrate and lipid metabolism. Optimal nutritional therapy should combine balanced diet, physical activity and personalized micronutrient support including multivitamin-multimineral complexes and phytonutrients.

  • Biological age on pause. The effect of nutraceuticals on endothelial dysfunction and aging processes

    by S. V. Orlova, E. V. Prokopenko, E. A. Nikitina, N. V. Balashova

    Aging is an inevitable process that includes an imbalance between antioxidant defenses and reactive oxygen species, changes in protein and mitochondrial turnover, telomere shortening, cellular senescence, epigenetic changes, and stem cell exhaustion. These conditions are associated with mild to moderate inflammation, which always accompanies the aging process and age-related diseases. The results of numerous studies indicate the existence of a complex biomolecular mechanism associated with age-related vascular dysfunction, which leads to oxidative stress, vascular remodeling, and endothelial dysfunction.

  • Features of body component composition and physiometric indices in women with non-alcoholic fatty liver disease

    by K. V. Vybornaya, S. V. Orlova, E. A. Nikitina, O. I. Tarasova, E. V. Prokopenko, A. N. Vodolazkaya, N. V. Balashova, I. S. Minosyan

    NAFLD is becoming an increasingly common disease that affects more than 25% of adults worldwide. If specific examination for NAFLD is not performed, this condition usually proceeds asymptomatically until the development of severe and potentially irreversible liver failure. Since the initial stage of NAFLD has no clinical manifestations and is poorly diagnosed, and is more often manifested in women, the aim of our study was to identify some features of the component composition of the body and physiometric indicators characteristic of this group of patients.

  • Undifferentiated connective tissue dysplasia and skin: what to do? Dietitian’s position

    by E. A. Nikitina, S. V. Orlova, T. T. Batysheva, N. V. Balashova, M. V. Alekseeva

    Undifferentiated connective tissue dysplasia (UCTD) is a common hidden diagnosis at a cosmetologist and dermatologist appointment, which can affect the prognosis, choice of procedure and patient management tactics. Being a genetically determined disorder of connective tissue formation and manifested by polymorphic changes in the skin, joints, blood vessels and internal organs, UCTD has no clear diagnostic criteria, which complicates timely diagnostics. A particular problem is premature aging, which in patients with UCTD is ahead of biological age by an average of 8 years, and impaired full tissue reparation against the background of UCTD. These changes are due to impaired synthesis of collagen, elastin and glycosaminoglycans. Since UCTD is a genetic pathology, it cannot be completely eliminated, but an integrated approach, including diet therapy and correction of micronutrient deficiencies, can slow down the progression of dysplastic changes and improve reparative processes after hardware-based and injectable cosmetology procedures. This review examines key nutrients that affect connective tissue metabolism, as well as current data on the effectiveness of diet therapy and dietary supplements for UCTD.

  • Native type II collagen in musculoskeletal disorders: current practice and future directions

    by E. A. Nikitina, S. V. Orlova, T. T. Batysheva, N. V. Balashova, M. V. Alekseeva

    Collagen is a primary structural protein of connective tissue, accounting for over a quarter of all body proteins. Among 29 known collagen types, type II collagen is particularly significant as it forms the foundation of articular cartilage. Unlike hydrolyzed forms, native type II collagen (UC–II) maintains its original chemical structure, enabling it to function as an oral tolerance inducer. Clinical studies demonstrate effectiveness of UC–II in reducing inflammation, alleviating pain, and improving joint function in osteoarthritis and rheumatoid arthritis. A promising development direction involves marinederived collagen preparations with enhanced safety profiles. Large-scale studies are needed to optimize dosage regimens and administration methods.

  • Vitamin D: What do we know by 2024? A review of the evidence on the effects of vitamin D supplementation on the human body

    by S. V. Orlova, E. A. Nikitina, A. N. Vodolazkaya, T. T. Batysheva, M. V. Alekseeva, N. V. Balashova, Yu. A. Pigareva, E. V. Prokopenko

    Vitamin D plays an import role in the regulation of calcium-phosphorus metabolism, metabolic processes and the cell cycle.Over the years, the mechanisms of molecular action of vitamin D in various cells, organs and tissues have been well studied. The widespread prevalence of vitamin D deficiency, established on the basis of laboratory diagnostics, has led to the development and implementation of programs for the correction of hypovitaminosis D. However, the question of the clinical effectiveness of these programs remains open. In this article, we review studies and meta-analyses of data that have assessed the preventive and therapeutic efficacy and safety of physiological and high doses of vitamin D.


  • Molecular mechanisms of action of DIM and its clinical application

    by E. A. Nikitina, S. V. Orlova, T. T. Batysheva, N. V. Balashova, M. V. Alekseeva, A. N. Vodolazkaya, E. V. Prokopenko, Kh. A. Magomedova

    Optimal nutrition requires complete provision of the human needs not only for energy, macro- and micronutrients, but also for minor biologically active substances. Some of the most promising chemoprotectors are glucosinolates and their active derivatives, such as 3,3’-diindolylmethane (DIM). DIM has the ability to inhibit the development and progression of neoplasia by regulating multiple intracellular signaling pathways. Currently, the clinical efficacy of DIM is being studied in breast and prostate cancer, and the possibility of using DIM’s antioxidant and anti-inflammatory properties in neurodegenerative, metabolic and immune diseases is being investigated.